Kenvue Inc.

Equities

KVUE

US49177J1025

Personal Products

Market Closed - Nyse 04:00:02 2024-07-12 pm EDT 5-day change 1st Jan Change
18.34 USD +2.34% Intraday chart for Kenvue Inc. +0.16% -14.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Common Stock of Kenvue Inc. are subject to a Lock-Up Agreement Ending on 14-JUL-2024. CI
UBS Adjusts Kenvue Price Target to $20 From $22, Maintains Neutral Rating MT
Citigroup Adjusts Kenvue's Price Target to $20 From $21 MT
Kenvue Inc.(NYSE:KVUE) dropped from Russell Top 200 Growth Index CI
Kenvue Inc.(NYSE:KVUE) dropped from Russell Top 200 Value Index CI
Kenvue Inc.(NYSE:KVUE) dropped from Russell Top 200 Index CI
Kenvue Inc.(NYSE:KVUE) dropped from Russell 3000E Growth Index CI
Kenvue Inc.(NYSE:KVUE) dropped from Russell 3000 Growth Index CI
Kenvue Inc.(NYSE:KVUE) added to Russell Midcap Index CI
Kenvue Inc.(NYSE:KVUE) added to Russell Midcap Value Index CI
Kenvue Inc.(NYSE:KVUE) dropped from Russell 1000 Growth Index CI
Transcript : Kenvue Inc. Presents at 21st Annual dbAccess Global Consumer Conference 2024, Jun-04-2024 02:45 PM
Some of the biggest splits in Corporate America RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies RE
Goldman Sachs Adjusts Kenvue Price Target to $21 From $20 MT
Ten key beauty players Our Logo
Kenvue Prices Secondary Common Stock Offering MT
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe MT
J&J: stake in Kenvue to be sold off CF
J&J to Sell Remaining Stake in Kenvue Spinoff DJ
Sector Update: Consumer Stocks Gain Premarket Monday MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes MT
J&J to exit Kenvue, a year after spinoff RE
J&J to sell all shares in spun-off unit Kenvue RE
Chart Kenvue Inc.
More charts
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: - health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.); - other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.). Product marketing is assured through direct sales, distributors and the Internet.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
18.34 USD
Average target price
22.32 USD
Spread / Average Target
+21.72%
Consensus
  1. Stock Market
  2. Equities
  3. KVUE Stock
  4. News Kenvue Inc.
  5. UBS Adjusts Kenvue Price Target to $20 From $22, Maintains Neutral Rating